HDAC9 and breast cancer: It has been reported that the HDAC inhibitor MS-275 can sensitize TRAIL-resistant breast cancer xenografts in nude mice through upregulation of DR4 and DR5 TRAIL receptors, inducing apoptosis, tumor cell growth inhibition, angiogenesis, and metastasis.